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Purpose

Background
• Trauma continues to be a significant contributing factor in

Primary objective: to examine the relationship between
missed prophylactic enoxaparin doses and rates of VTE
formation in the orthopedic trauma population at ACMC

death in the younger population, accounting for the leading
cause of preventive death in people younger than forty- four
(1).

• It has been extensively studied that physical trauma places

Secondary objective: to determine if there is an increase
in the incidence of bleeding complications during
orthopedic surgery in patients with traumatic orthopedic
injuries who receive pharmacologic VTE prophylaxis preand post-operatively

patients in a hypercoagulable state (2).
• Many factors contribute to venous thromboembolism, or VTE,
rates, and can be as high as 65% in the absence of
thromboprophylaxis (3).
• Advocate Christ Medical Center’s (ACMC) Department of
Orthopedic Surgery has subjectively observed increased
amounts of intraoperative bleeding with enoxaparin
administration and ACMC’s VTE prophylaxis guidelines for
trauma patients were modified due to the orthopedic
surgeons’ concerns.
• Previously, VTE prophylaxis for all trauma patients at ACMC
was administered pre- and post-orthopedic intervention
without interruption.
• Now, all trauma patients at ACMC undergoing orthopedic
surgery have their VTE prophylaxis dose held immediately
before surgery.

• To date, only a few studies have examined the impact of
missed prophylactic doses on patients, specifically trauma
patients.
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Methods
•
•
•
•

IRB-approved, single center, retrospective review
Data pulled from trauma registry and electronic medical
records for all trauma patients
January 1, 2010 – July 31, 2021
Patients with orthopedic injuries admitted to ACMC under
the care of the trauma service
Inclusion Criteria

Exclusion Criteria

• Patients admitted to the
trauma service with an
orthopedic injury (long
bone or pelvic fractures)
• 1/1/2010-07/31/21
• Age ≥ 18 years
• Patient undergoes
orthopedic surgery
during the hospital stay

• Pregnancy
• History of venous thromboembolism
• Contraindications to pharmacologic VTE
prophylaxis (thrombocytopenia (<50K),
history of heparin induced
thrombocytopenia, presence of a spinal
epidural hematoma, allergy to
enoxaparin or heparin)
• Patients receiving therapeutic
anticoagulation or anti-platelets preinjury (therapeutic dose enoxaparin,
heparin infusion, warfarin, dabigatran,
rivaroxaban, apixaban, ticagrelor,
aspirin, clopidogrel, and prasugrel)

Outcomes
• Primary endpoint: incidence of VTE (DVT/PE)
• Secondary endpoint: incidence of bleeding
complications

Results
• 79 patients included
• 61 patients (77%) experienced interruption in
enoxaparin prophylaxis
• 3 patients (3.8%) developed a VTE
• 0% VTE rate (0/18 patients) in the uninterrupted
therapy group vs. 5% VTE rate (3/61 patients) in
the interrupted therapy group
• Median (ICQ) number of missed doses of VTE
prophylaxis was 1 (1-3) in the no VTE group
compared with 3 (2-7) in the VTE group (p=0.08)
• Statistically significant increase in the median (ICQ)
hospital length of stay in the VTE group compared
to the no VTE group (12 (12-19) vs. 5 (3-8), p=0.01)
• No statistically significant difference in coagulation
variables
• 16.7% (3/18) of patients in the uninterrupted
group required an intervention due to bleeding vs.
0.03% (2/61) of patients in the interrupted therapy
group
• Median (ICQ) number of surgeries was significantly
higher in the VTE group compared to the no VTE
group (3 (2-4) vs. 1(1-1), p = 0.0003)

Conclusions

• There is a trend towards an increase in VTE rates with
interrupted VTE prophylaxis doses.
• Patients who develop a VTE may have an increased
hospital length of stay.
• More than one orthopedic surgery significantly
increases VTE rate.
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